Evidence map›Paper›PMID 31852548›Full record

ArticleBMC pharmacology & toxicology2019

Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegans.

Fabiana Gomes Nascimento Soares, Gabriela Göethel, Luciano Porto Kagami, Gustavo Machado das Neves, Elisa Sauer, Estefania Birriel, Javier Varela, Itamar Luís Gonçalves, Gilsane Von Poser, Mercedes González and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pharmacology & toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Fabiana Gomes Nascimento SoaresLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Gabriela GöethelLaboratório Toxicologia/LATOX, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Luciano Porto KagamiLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Gustavo Machado das NevesLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Elisa SauerLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Estefania BirrielFacultad de Ciencias-Facultad de Química, Universidad de la República, Montevideo, Uruguay.
Javier VarelaFacultad de Ciencias-Facultad de Química, Universidad de la República, Montevideo, Uruguay.
Itamar Luís GonçalvesLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Gilsane Von PoserLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Mercedes GonzálezFacultad de Ciencias-Facultad de Química, Universidad de la República, Montevideo, Uruguay.
Daniel Fábio KawanoFaculdade de Ciências Farmacêuticas, Universidade Estadual de Campinas, Campinas, SP, Brazil.
Fávero Reisdorfer PaulaUniversidade Estadual do Oeste do Paraná, Centro de Ciências Médicas e Farmacêuticas, Cascavel, PR, Brazil.
Eduardo Borges de MeloCentro de Ciências Médicas e Farmacêuticas, Universidade Estadual do Oeste do Paraná, Cascavel, PR, Brazil.
Solange Cristina GarciaLaboratório Toxicologia/LATOX, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Hugo CerecettoFacultad de Ciencias-Facultad de Química, Universidad de la República, Montevideo, Uruguay.
Vera Lucia Eifler-LimaLaboratório de Síntese Orgânica Medicinal/LaSOM, Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. veraeifler@ufrgs.br.
Universidade Federal do Rio Grande do Sul · BRUniversidad de la República · UYUniversidade Estadual do Oeste do Paraná · BRUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChagas disease (CD) is a tropical parasitic disease. Although the number of people infected is very high, the only drugs available to treat CD, nifurtimox (Nfx) and benznidazole, are highly toxic, particularly in the chronic stage of the disease. Coumarins are a large class of compounds that display a wide range of interesting biological properties, such as antiparasitic. Hence, the aim of this work is to find a good antitrypanosomal drug with less toxicity. The use of simple organism models has become increasingly attractive for planning and simplifying efficient drug discovery. Within these models, Caenorhabditis elegans has emerged as a convenient and versatile tool with significant advantages for the toxicological potential identification for new compounds.

methodsTrypanocidal activity: Forty-two 4-methylamino-coumarins were assayed against the epimastigote form of Trypanosoma cruzi (Tulahuen 2 strain) by inhibitory concentration 50% (IC

resultsTwo of these coumarins demonstrated near equipotency to Nifurtimox (IC

conclusionTwo coumarins (11 h and 11 g) showed activity against T. cruzi epimastigote similar to Nifurtimox, however with lower toxicity in both LD

Indexed as

AnimalsCaenorhabditis elegansCoumarinsInhibitory Concentration 50Lethal Dose 50Molecular StructureParasitic Sensitivity TestsStructure-Activity RelationshipTrypanocidal AgentsTrypanosoma cruziCoumarinsTrypanocidal AgentsCaenorhabditis elegansChagas diseaseCoumarinsStructure-activity relationshipTrypanosoma cruzi

Identifiers

PMID31852548
PMCPMC6921407
OpenAlexW2995413946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.